Exosomes derived from human umbilical cord mesenchymal stem cells alleviate otitis media in C57BL/6 mice via the miR-149-3p/NOX2 axis.
6 affiliations
- 1Shandong Key Lab of Complex Medical Intelligence and Aging, School of Special Education and Rehabilitation, Shandong Medical and Pharmaceutical University, Yantai, Shandong, China.
- 2Rehabilitation Department, Taishan Vocational College of Nursing, Taian, Shandong, China.
- 3Department of Rehabilitation Medicine, Yantaishan Hospital, Yantai, Shandong, China.
- 4Department of Otolaryngology, Head and Neck Surgery, Institute of Otolaryngology, Affiliated Hospital of Shandong Medical and Pharmaceutical University, Binzhou, Shandong, China.
- 5Shandong Key Lab of Complex Medical Intelligence and Aging, School of Special Education and Rehabilitation, Shandong Medical and Pharmaceutical University, Yantai, Shandong, China. Electronic address: [email protected].
- 6Shandong Key Lab of Complex Medical Intelligence and Aging, School of Special Education and Rehabilitation, Shandong Medical and Pharmaceutical University, Yantai, Shandong, China. Electronic address: [email protected].
Abstract
Otitis media (OM) is a highly prevalent disease leading to hearing loss in children. Current clinical treatment for OM primarily relies on antibiotics; however, the overuse of antibiotics exacerbates bacterial resistance, posing a global public health challenge. Therefore, novel therapeutic strategies for OM are urgently needed. Human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSCs-Exos) have demonstrated significant therapeutic potential in various diseases, but their efficacy in OM remains unclear. In this study, we induced C57BL/6 mice with lipopolysaccharide (LPS) to establish an OM mouse model. OM mice were treated with exosomes derived from human umbilical cord mesenchymal stem cells (hUCMSCs-Exos), through two administration methods, tympanic membrane (TM) and tail vein (TV) injection. Our results showed that hUCMSCs-Exos significantly alleviated OM in mice, as evidenced by improved auditory function, reduced middle ear mucosal thickening, decreased purulent exudation, downregulated expression of inflammatory cytokines, and alleviated oxidative stress. Multi-omics analysis revealed significant alterations in NADPH Oxidase 2 (NOX2) expression and its upstream regulator miR-149-3p within the HIF-1 signaling pathway. qRT-PCR and Western blot confirmed that hUCMSCs-Exos upregulated miR-149-3p and suppressed NOX2 expression, thereby reducing reactive oxygen species (ROS) generation, and consequently alleviating otitis media inflammation. Furthermore, in vivo gain- and loss-of-function experiments demonstrated that miR-149-3p is a key mediator in hUCMSCs-Exos-regulated NOX2 expression and downstream inflammatory responses. Comparative analysis of administration routes revealed that local TM injection yielded superior therapeutic outcomes compared to systemic TV delivery. In summary, our findings indicate that hUCMSCs-Exos may alleviate LPS-induced OM in mice by delivering miR-149-3p to target and inhibit NOX2 expression and its downstream inflammatory cascade, providing a theoretical basis for hUCMSCs-Exos as a novel non-antibiotic therapeutic strategy for OM.
Related
- Mesenchymal stem cell-derived exosomes alleviate renal interstitial fibrosis via pVHL-mediated HIF-1α ubiquitination and degradation
- Mesenchymal Stem Cell-Derived Exosomes for Bone Regeneration: Modification Strategies and miRNA-Mediated Modulation of Osteogenic Signaling
- Exosomes derived from bone substitute-induced gingival mesenchymal stem cells promote angiogenesis.
- Bone Marrow Mesenchymal Stem Cell-Derived Exosomal miR-451a Inhibits Macrophage M1 Polarization Through the TLR4/PI3K/AKT Signaling Pathway to Alleviate Acute Lung Injury.
- Engineered mesenchymal stem cell-derived extracellular vesicles overexpressing miR-146a alleviate neuroinflammation in Alzheimer's disease.
BibTeX
@article{zhang2026exosomes,
title = {{Exosomes derived from human umbilical cord mesenchymal stem cells alleviate otitis media in C57BL/6 mice via the miR-149-3p/NOX2 axis.}},
author = {Kai Zhang and Lihuan Tang and Mengxian Du and Yongqin Mu and Yuancheng Wu and Ruishuang Geng and Xiaolin Zhang and Qingyin Zheng and Tihua Zheng and Bo Li},
journal = {Redox biology},
year = {2026},
month = oct,
doi = {10.1016/j.redox.2026.104425},
url = {https://europepmc.org/article/MED/42863262},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Exosomes derived from human umbilical cord mesenchymal stem cells alleviate otitis media in C57BL/6 mice via the miR-149-3p/NOX2 axis.
AU - Kai Zhang
AU - Lihuan Tang
AU - Mengxian Du
AU - Yongqin Mu
AU - Yuancheng Wu
AU - Ruishuang Geng
AU - Xiaolin Zhang
AU - Qingyin Zheng
AU - Tihua Zheng
AU - Bo Li
PY - 2026
DA - 2026/10/08
JO - Redox biology
DO - 10.1016/j.redox.2026.104425
UR - https://europepmc.org/article/MED/42863262
AB - Otitis media (OM) is a highly prevalent disease leading to hearing loss in children. Current clinical treatment for OM primarily relies on antibiotics; however, the overuse of antibiotics exacerbates bacterial resistance, posing a global public health challenge. Therefore, novel therapeutic strategies for OM are urgently needed. Human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSCs-Exos) have demonstrated significant therapeutic potential in various diseases, but their efficacy in OM remains unclear. In this study, we induced C57BL/6 mice with lipopolysaccharide (LPS) to establish an OM mouse model. OM mice were treated with exosomes derived from human umbilical cord mesenchymal stem cells (hUCMSCs-Exos), through two administration methods, tympanic membrane (TM) and tail vein (TV) injection. Our results showed that hUCMSCs-Exos significantly alleviated OM in mice, as evidenced by improved auditory function, reduced middle ear mucosal thickening, decreased purulent exudation, downregulated expression of inflammatory cytokines, and alleviated oxidative stress. Multi-omics analysis revealed significant alterations in NADPH Oxidase 2 (NOX2) expression and its upstream regulator miR-149-3p within the HIF-1 signaling pathway. qRT-PCR and Western blot confirmed that hUCMSCs-Exos upregulated miR-149-3p and suppressed NOX2 expression, thereby reducing reactive oxygen species (ROS) generation, and consequently alleviating otitis media inflammation. Furthermore, in vivo gain- and loss-of-function experiments demonstrated that miR-149-3p is a key mediator in hUCMSCs-Exos-regulated NOX2 expression and downstream inflammatory responses. Comparative analysis of administration routes revealed that local TM injection yielded superior therapeutic outcomes compared to systemic TV delivery. In summary, our findings indicate that hUCMSCs-Exos may alleviate LPS-induced OM in mice by delivering miR-149-3p to target and inhibit NOX2 expression and its downstream inflammatory cascade, providing a theoretical basis for hUCMSCs-Exos as a novel non-antibiotic therapeutic strategy for OM.
SN - 2213-2317
ER -